Skip to main content

Table 1 Patient and sample characteristics (n = 101)

From: Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations

 

n (%)

Diagnostic category

 Solid tumors

65 (64)

 Hematologic conditions

36 (36)

Gender

 Male

60 (59)

 Female

41 (41)

Age (years)

 0–5

35 (34)

 6–12

30 (30)

 13–17

20 (20)

 ≥18

16 (16)

Samples tested (n = 120)

 Primary disease

85 (71)

 Relapse/refractory

35 (29)

Platform (n = 120)

 Cancer WES with transcriptome

63 (53)

 Cancer WES

19 (16)

 Constitutional WES

22 (18)

 Transcriptome only

3 (2)

 Targeted panel (467 genes)

13 (11)

Normal tissue source (n = 104)

 Blood

78 (74)

 Buccal swab

23 (23)

 Unaffected tissue

3 (3)

  1. WES whole-exome sequencing